KLP Kapitalforvaltning AS Makes New Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

KLP Kapitalforvaltning AS purchased a new position in Amicus Therapeutics, Inc. ( NASDAQ:FOLD – Free Report ) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 49,000 shares of the biopharmaceutical company’s stock, valued at approximately $462,000.

Several other institutional investors and hedge funds have also made changes to their positions in FOLD. AXQ Capital LP purchased a new position in Amicus Therapeutics in the 4th quarter valued at about $171,000. Sciencast Management LP purchased a new position in shares of Amicus Therapeutics during the fourth quarter valued at approximately $100,000.



Semanteon Capital Management LP boosted its position in Amicus Therapeutics by 40.9% during the fourth quarter. Semanteon Capital Management LP now owns 149,156 shares of the biopharmaceutical company’s stock worth $1,405,000 after acquiring an additional 43,288 shares during the last quarter.

Teacher Retirement System of Texas grew its stake in Amicus Therapeutics by 18.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,927 shares of the biopharmaceutical company’s stock worth $621,000 after acquiring an additional 10,218 shares during the period.

Finally, Xponance Inc. raised its holdings in Amicus Therapeutics by 11.9% in the 4th quarter.

Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock valued at $200,000 after acquiring an additional 2,249 shares during the last quarter. Amicus Therapeutics Trading Up 0.

1 % NASDAQ FOLD opened at $8.00 on Friday. The firm has a market capitalization of $2.

46 billion, a price-to-earnings ratio of -44.44, a PEG ratio of 1.51 and a beta of 0.

69. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.

42 and a current ratio of 3.39. Amicus Therapeutics, Inc.

has a one year low of $7.72 and a one year high of $12.65.

The company’s 50 day moving average price is $9.16 and its 200 day moving average price is $9.88.

Analyst Upgrades and Downgrades Get Our Latest Stock Analysis on Amicus Therapeutics About Amicus Therapeutics ( Free Report ) Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. Recommended Stories Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.

com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. ( NASDAQ:FOLD – Free Report ). Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.

com's FREE daily email newsletter ..